Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials

Fluvoxamine is widely prescribed as an antidepressant. Recent studies show the drug may have a clinical benefit in treating COVID-19. We aimed to perform a meta-analysis of the existing randomized trials of fluvoxamine compared with placebo on the early treatment of COVID-19 patients. We included on...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Christina M., Harari, Ofir, Chernecki, Cameron, Thorlund, Kristian, Forrest, Jamie I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128689/
https://www.ncbi.nlm.nih.gov/pubmed/35263710
http://dx.doi.org/10.4269/ajtmh.21-1310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128689/
https://www.ncbi.nlm.nih.gov/pubmed/35263710
http://dx.doi.org/10.4269/ajtmh.21-1310

Ejemplares similares